You Should Watch These: Gilead Sciences (NASDAQ:GILD), Netflix (NASDAQ:NFLX), Zynerba Pharmaceuticals (NASDAQ:ZYNE), B2Gold Corp. (NYSEMKT:BTG)

On 18 March, Symantec Corporation (NASDAQ:SYMC) shares fell -0.69% and was closed at $18.60. SYMC EPS growth in last 5 year was 7.70%. Symantec Corporation (NASDAQ:SYMC) year to date (YTD) performance is 10.85%.

Symantec Corporation (NASDAQ:SYMC) declared a special dividend. Investors of record on Tuesday, March 8th will be paid a dividend of 4.00 per share on Tuesday, March 22nd. This represents a yield of 3.12%. The ex-dividend date of this dividend is Friday, March 4th.

Gilead Sciences Inc. (NASDAQ:GILD) shares moved up 0.83% in last trading session and ended the day at $90.27. GILD Gross Margin is 87.70% and its has a return on assets of 40.20%. Gilead Sciences Inc. (NASDAQ:GILD) quarterly performance is -12.23%.

On 15 March, Gilead Sciences Inc. (NASDAQ:GILD) has halted several patient studies of its cancer drug, Zydelig, because of increased risk of death and serious side effects.

Netflix, Inc. (NASDAQ:NFLX) caters to the Services space. It has a net profit margin of 1.80% and weekly performance is 3.54%. On the last day of trading company shares ended up at $101.12. Netflix, Inc. (NASDAQ:NFLX) distance from 50-day simple moving average (SMA50) is 12.26%.

On 19 March, Netflix, Inc. (NASDAQ:NFLX) will invest $90 million in the Max Landis scripted cop thriller starring Will Smith titled, Bright. Directed by David Ayer and co-starring Joel Edgerton, the fantastical film is one of the largest spec deals for a writer in years. Deadline reports the deal includes “north of $3M for the Landis script,” and is intended to launch a franchise. The film will cost around $45 million to shoot – half of that in production costs, and another half for talent – making this Netflix’s largest movie deal.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) shares increased 7.73% in last trading session and ended the day at $10.73. ZYNE has a return on assets of -43.30%. Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) quarterly performance is -19.63%.

On 14 March, Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) reported financial results for the quarter and year ended December 31, 2015, and provided an overview of recent operational highlights. The Company ended 2015 with $41.5 million in cash and cash equivalents and believes its current cash position will support its operating plan through Phase 2 data readout for the five indications of ZYN002 and ZYN001.

B2Gold Corp. (NYSEMKT:BTG) caters to the Basic Materials space. Its weekly performance is 21.97%. On the last day of trading company shares ended up at $1.61. B2Gold Corp. (NYSEMKT:BTG) distance from 50-day simple moving average (SMA50) is 61.24%.

B2Gold Corp. (NYSEMKT:BTG) is pleased to announce that it has received approvals for Gold Prepaid Sales Financing Arrangements (“Prepaid Sales”) of up to $120 million, has signed a commitment letter to enter into a Euro equivalent of $81 million term mining Equipment Facility (“The Facility”) and has increased the size of the Otjikoto Equipment Loan Facility. All dollar figures are in United States dollars unless otherwise indicated.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *